BIND Biosciences, Inc. is Granted Five U.S. Patents Covering BIND-014 and Accurin Platform
Published: Sep 20, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that the United States Patent and Trademark Office has recently issued five U.S. patents to the company. The patents cover BIND-014,the company’s lead Accurin product candidate for solid cancer tumors, and its Medicinal NanoengineeringTM platform which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.